Results 271 to 280 of about 361,630 (339)

Glycated Hemoglobin and Risk of Sternal Wound Infection After Isolated Coronary Surgery

open access: gold, 2016
Giuseppe Gatti   +25 more
openalex   +2 more sources

PIONEER REAL Spain: A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study evaluated clinical outcomes of oral semaglutide treatment in adults with type 2 diabetes (T2D) in a real‐world setting in Spain as part of the 13‐country PIONEER REAL programme. Materials and Methods This multicentre, prospective, non‐interventional, single‐arm study (NCT05443334) followed participants for 34–44 weeks ...
Elías Delgado Álvarez   +10 more
wiley   +1 more source

Efficacy and safety of danuglipron (PF‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This randomized, double‐blind, placebo‐controlled Phase 2b study aimed to assess the efficacy, safety, and tolerability of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in adults with obesity. Materials and Methods Eligible participants (aged 18–75 years; with obesity, without diabetes)
Clare Buckeridge   +9 more
wiley   +1 more source

Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Globally, cardiovascular diseases (CVDs) account for around one‐third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon‐like peptide‐1 (GLP‐1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all‐cause ...
Naveed Sattar   +5 more
wiley   +1 more source

Ethnicity and socioeconomic status do not influence glycaemic outcomes of a tubeless hybrid closed‐loop system (Omnipod® 5) in adults with type 1 diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We aimed to evaluate real‐world glycaemic outcomes of a tubeless hybrid closed‐loop (HCL) insulin delivery system in type 1 diabetes (T1D), exploring the influence of ethnicity and socioeconomic status from a publicly funded system with universal access. Materials and Methods This was a retrospective observational study in adults with T1D
Ananthi Anandhakrishnan   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy